港股異動 | 君實生物(1877.HK)漲超5%創新高 完成A股發行 明日上市
格隆匯7月14日丨君實生物-B(1877.HK)高開高走,盤中高見64.7港元續創歷史新高,現報64.55港元,漲5.82%,暫成交835萬港元,最新總市值562億港元。君實生物今晨發公告稱,公司已完成A股發行,公司A股將於7月15日(即明日)在上交所科創板上市並開始買賣。此外,公司與Revitope簽署了研發合作及許可協議,公司將獲得協議中產品在全球範圍內的獨佔許可。協議的簽署將有助於公司與Revitope各自的平台技術優勢互補,將對公司業務發展產生積極影響。 公司昨日午間亦宣佈,自7月15日起,公司的股份名稱及股份簡稱將不再加上標記“B”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.